Dendritic Cells Transfected with Adenoviral Vectors as Vaccines

  • Joseph Senesac
  • Dmitry Gabrilovich
  • Samuel Pirruccello
  • James E. Talmadge
Part of the Methods in Molecular Biology book series (MIMB, volume 1139)


Dendritic cells (DCs) are critical to the initiation of a T-cell response. They constitute the most potent antigen-presenting cell (APC) endowed with the unique capacity to stimulate an antigen-specific T-cell responses by naïve T cells. Adenoviruses (Ad) have high transduction efficiency for many cell types including cells of hematopoietic origin independent of their mitotic status, and replication-defective Ad have demonstrated a safety profile clinically. Further, Ad vectors provide a high level of transgene expression, and Ad-transduced DCs can effectively present antigenic proteins. In this chapter, we outline a functionally closed, good manufacturing protocol for the differentiation of monocytes into DCs and transduction by Ad vectors. Basic functional and phenotypic release assays are provided, as well as contrasting research approaches for Ad-transduced DC-based vaccines.

Key words

Monocytes Dendritic cells Adenovirus Vaccine Release assays 



The authors would like to thank Richard E. Neubiser, Afc, for his contributions to this chapter and Alice S. Cole for her assistance in with manuscript preparation.


  1. 1.
    Kantoff PW et al (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411–422PubMedCrossRefGoogle Scholar
  2. 2.
    Morse MA et al (1999) Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res 59:56–58PubMedGoogle Scholar
  3. 3.
    Reichardt VL et al (1999) Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma—a feasibility study. Blood 93:2411–2419PubMedGoogle Scholar
  4. 4.
    Gallo P et al (2005) Adenovirus as vehicle for anticancer genetic immunotherapy. Gene Ther 12(Suppl 1):S84–S91PubMedCrossRefGoogle Scholar
  5. 5.
    Sakurai F (2003) Characterization of in vitro and in vivo gene transfer properties of adenovirus serotype 35 vector. Mol Ther 8:813–821PubMedCrossRefGoogle Scholar
  6. 6.
    Schoggins JW, Falck-Pedersen E (2006) Fiber and penton base capsid modifications yield diminished adenovirus type 5 transduction and proinflammatory gene expression with retention of antigen-specific humoral immunity. J Virol 80:10634–10644PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Rouard H et al (2000) Adenoviral transduction of human ‘clinical grade’ immature dendritic cells enhances costimulatory molecule expression and T-cell stimulatory capacity. J Immunol Methods 241:69–81PubMedCrossRefGoogle Scholar
  8. 8.
    Lyakh LA et al (2002) Adenovirus type 5 vectors induce dendritic cell differentiation in human CD14(+) monocytes cultured under serum-free conditions. Blood 99:600–608PubMedCrossRefGoogle Scholar
  9. 9.
    Cao H et al (2000) In vitro generation of dendritic cells from human blood monocytes in experimental conditions compatible for in vivo cell therapy. J Hematother Stem Cell Res 9:183–194PubMedCrossRefGoogle Scholar
  10. 10.
    Lemarie C et al (2007) Purification of monocytes from cryopreserved mobilized apheresis products by elutriation with the Elutra device. J Immunol Methods 318:30–36PubMedCrossRefGoogle Scholar
  11. 11.
    Gulen D et al (2008) Closing the manufacturing process of dendritic cell vaccines transduced with adenovirus vectors. Int Immunopharmacol 8:1728–1736PubMedCrossRefGoogle Scholar
  12. 12.
    Zhou Y et al (2003) Commercial scale production of dendritic cells for cancer immunotherapy. Proc Am Assoc Cancer Res 44:2876AGoogle Scholar
  13. 13.
    Thurner B et al (1999) Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. J Immunol Methods 223:1–15PubMedCrossRefGoogle Scholar
  14. 14.
    Whiteside TL et al (2009) Production of a dendritic cell-based vaccine containing inactivated autologous virus for therapy of patients with chronic human immunodeficiency virus type 1 infection. Clin Vaccine Immunol 16:233–240PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    Padley DJ et al (2001) Mature myeloid dendritic cells for clinical use prepared from cd14+ cells isolated by immunomagnetic adsorption. J Hematother Stem Cell Res 10:427–429PubMedCrossRefGoogle Scholar
  16. 16.
    Wong EC et al (2002) Development of a closed-system process for clinical-scale generation of DCs: evaluation of two monocyte-enrichment methods and two culture containers. Cytotherapy 4:65–76PubMedCrossRefGoogle Scholar
  17. 17.
    Bender J (2000) Next generation clinical systems for the production of dendritic cells. Clin Appl Immunol Rev 1:37–44CrossRefGoogle Scholar
  18. 18.
    Suen Y et al (2001) Comparison of monocyte enrichment by immuno-magnetic depletion or adherence for the clinical-scale generation of DC. Cytotherapy 3:365–375PubMedCrossRefGoogle Scholar
  19. 19.
    Gajdosikova A et al (2006) Acute toxicity of magnetic nanoparticles in mice. Neuro Endocrinol Lett 27(Suppl 2):96–99PubMedGoogle Scholar
  20. 20.
    Berger T et al (2005) Efficient elutriation of monocytes within a closed system (Elutra™) for clinical-scale generation of dendritic cells. J Immunol Methods 298:61–72PubMedCrossRefGoogle Scholar
  21. 21.
    Stockwin LH et al (2002) Engineered expression of the Coxsackie B and adenovirus receptor (CAR) in human dendritic cells enhances recombinant adenovirus-mediated gene transfer. J Immunol Methods 259:205–215PubMedCrossRefGoogle Scholar
  22. 22.
    Verhaagh S et al (2006) Human CD46-transgenic mice in studies involving replication-incompetent adenoviral type 35 vectors. J Gen Virol 87:255–265PubMedCrossRefGoogle Scholar
  23. 23.
    Lore K et al (2007) Myeloid and plasmacytoid dendritic cells are susceptible to recombinant adenovirus vectors and stimulate polyfunctional memory T cell responses. J Immunol 179:1721–1729PubMedCentralPubMedGoogle Scholar
  24. 24.
    Dietz AB et al (2001) Maturation of dendritic cells infected by recombinant adenovirus can be delayed without impact on transgene expression. Gene Ther 8:419–423PubMedCrossRefGoogle Scholar
  25. 25.
    Adams WC, Loré K (2011) Recombinant adenovirus vector infection of human dendritic cells. DOI:10.5772/20255Google Scholar
  26. 26.
    Bergelson JM et al (1997) Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5. Science 275:1320–1323PubMedCrossRefGoogle Scholar
  27. 27.
    Hemmi S et al (1998) The presence of human coxsackievirus and adenovirus receptor is associated with efficient adenovirus-mediated transgene expression in human melanoma cell cultures. Hum Gene Ther 9:2363–2373PubMedCrossRefGoogle Scholar
  28. 28.
    Tillman BW et al (1999) Maturation of dendritic cells accompanies high-efficiency gene transfer by a CD40-targeted adenoviral vector. J Immunol 162:6378–6383PubMedGoogle Scholar
  29. 29.
    Einfeld DA et al (2001) Reducing the native tropism of adenovirus vectors requires removal of both CAR and integrin interactions. J Virol 75:11284–11291PubMedCentralPubMedCrossRefGoogle Scholar
  30. 30.
    Papagatsias T et al (2008) Activity of different vaccine-associated promoter elements in human dendritic cells. Immunol Lett 115:117–125PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Joseph Senesac
    • 1
  • Dmitry Gabrilovich
    • 2
  • Samuel Pirruccello
    • 3
  • James E. Talmadge
    • 3
  1. 1.Bellicum PharmaceuticalsHoustonUSA
  2. 2.H. Lee Moffitt Cancer CenterUniversity of South FloridaTampaUSA
  3. 3.University of Nebraska Medical CenterOmahaUSA

Personalised recommendations